Kinetin identified as a potential new SARS-CoV-2 antiviral compound

Feb. 6, 2023

Researchers from Fundacao Oswaldo Cruz (Fiocruz) have evaluated kinetin (MB-905) as an antiviral against SARS-CoV-2.